CytoSorbents Appoints Jiny Kim, MBA to its Board of Directors

About this update from Cytosorbents Corporation

[{"type":"text","content":"MONMOUTH JUNCTION, N.J. , April 5, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces the appointment of Ms. Jiny Kim, MBA to CytoSorbents' Board of Directors as a new independent director, effective immediately, for a term expiring at the Company's 2022 Annual Meeting, scheduled for June 7, 2022, at which time Ms. Kim is expected to stand for re-election. \n\n \n \n \n \n \n \n\n \nCytoSorbents Appoints Jiny Kim, MBA to its Board of DirectorsAl Kraus, Chairman of the Board of CytoSorbents stated, \"We are pleased to welcome Jiny as our new independent Board director. She has an extensive background in the medical device industry, with an impressive set of skills, experiences, and perspectives in U.S. and international commercialization, sales, marketing, and business development from leadership roles at market-leading companies like Zimmer Biomet, LivaNova, and Ethicon/Johnson & Johnson. She is expected to further strengthen and diversify the Board at a critical juncture for the Company as we target U.S. expansion and further international growth, and be invaluable in helping to guide the Company to the next level.\"\nJiny Kim is currently Vice President, Smart Implants, Technology & Data Solutions at Zimmer Biomet. In this role, she is responsible for leading the end-to-end program and product management for Zimmer Biomet's \"Smart Implant\" technology, including product development, data development, and market development. In addition, she is leading the launch of Persona IQ®, a first to market smart knee implant in the U.S. \nPrior to Zimmer Biomet, Ms. Kim held the position of Vice President of Global Marketing, Neuromodulation and Depression at LivaNova, where she led key initiatives in clinical and commercial areas to maximize the asset value globally. At Ethicon, Johnson & Johnson Medical Devices, she held multiple roles including in U.S. Sales and Marketing, Business Development (Licensing and Acquisition), and Strategic Global Marketing where she launched and managed significant brands through their full lifecycle. Ms. Kim also held multiple global marketing roles at Edwards Lifesciences in the Critical Care space. She began her medical device career as a post-MBA Opera...

More updates from Cytosorbents Corporation